本文選題：醫(yī)藥行業(yè) + 上市公司��； 參考：《南京航空航天大學》2016年碩士論文

【摘要】：改革開放以來,我國醫(yī)藥行業(yè)發(fā)展迅速,已經是國家重點扶持的戰(zhàn)略性產業(yè)。伴隨著醫(yī)療制度改革和農村醫(yī)療合作制度的推進,我國醫(yī)藥行業(yè)步入了穩(wěn)步發(fā)展的調整轉型時期。對我國醫(yī)藥行業(yè)的上市公司進行綜合績效評價,有利于了解我國醫(yī)藥行業(yè)的整體經營情況和發(fā)展?jié)摿?對各方利益相關者的決策都有借鑒意義。本文首先對國內外相關學者關于企業(yè)績效評價和醫(yī)藥企業(yè)績效評價研究情況進行了回顧和綜述,分析了我國醫(yī)藥行業(yè)的發(fā)展現狀。然而,在醫(yī)藥行業(yè)的績效評價中存在忽略行業(yè)特征,不考慮企業(yè)的社會責任,過分強調財務績效等一些突出問題,而且目前國內學術界對醫(yī)藥行業(yè)上市公司績效研究時,綜合績效評價較少,側重于財務指標體系的構建,忽視了企業(yè)應該承擔的社會責任。因此,結合醫(yī)藥行業(yè)上市公司發(fā)展現狀和特征,運用科學、有效的評價方法對醫(yī)藥行業(yè)上市公司的績效進行比較分析是一個亟待解決且意義重大的難題。本文以國有資產控股的醫(yī)藥行業(yè)上市公司為研究樣本,采用熵權法和突變級數法相結合的定量研究方法展開研究,主要研究內容包括:第一,闡述了本論文的研究背景、目的和意義、國內外研究現狀等;第二,對醫(yī)藥行業(yè)上市公司績效評價相關理論進行綜述,分別對績效、績效評價、企業(yè)績效評價基礎、企業(yè)績效評價指標體系和企業(yè)績效評價方法等進行了研究;第三,分析了醫(yī)藥行業(yè)的行業(yè)特征;第四,構建了醫(yī)藥行業(yè)上市公司績效評價指標體系,闡述了各指標的內涵和評價指標標準化處理和熵權法賦權原理;第五,研究了績效評價方法,分析了采用突變級數方法的優(yōu)勢;第六,根據國有資產控股的41家醫(yī)藥行業(yè)上市公司2014年的數據進行綜合分析;最后,本文從上市公司經營管理者層面提出了相關建議,并且就如何提高醫(yī)藥行業(yè)的整體績效提出針對性建議。
[Abstract]:Since the reform and opening up, China's pharmaceutical industry has developed rapidly and has become a strategic industry supported by the state. With the reform of medical system and the promotion of rural medical cooperation system, China's pharmaceutical industry has stepped into a period of steady development of adjustment and transformation. The comprehensive performance evaluation of the listed companies in the pharmaceutical industry of our country is beneficial to the understanding of the overall operating situation and development potential of the pharmaceutical industry in our country, and has reference significance to the decision-making of the stakeholders. Firstly, this paper reviews and summarizes the research on enterprise performance evaluation and pharmaceutical enterprise performance evaluation by domestic and foreign scholars, and analyzes the development status of pharmaceutical industry in China. However, there are some outstanding problems in the performance evaluation of pharmaceutical industry, such as neglecting the characteristics of the industry, not considering the social responsibility of the enterprise, and overemphasizing the financial performance. Moreover, when the domestic academic circles study the performance of the listed companies in the pharmaceutical industry at present, The comprehensive performance evaluation is less, focusing on the construction of financial index system and neglecting the social responsibility that enterprises should bear. Therefore, it is an urgent and significant problem to compare and analyze the performance of listed companies in the pharmaceutical industry by using scientific and effective evaluation methods combined with the development status and characteristics of listed companies in the pharmaceutical industry. In this paper, the listed companies in the pharmaceutical industry controlled by state-owned assets are taken as the research samples, and the quantitative research method combining entropy weight method and catastrophe series method is used to carry out the research. The main research contents are as follows: first, the research background of this paper is expounded. Purpose and significance, domestic and foreign research status quo; second, the pharmaceutical industry listed companies performance evaluation theory review, performance evaluation, performance evaluation, enterprise performance evaluation basis, The index system of enterprise performance evaluation and the methods of enterprise performance evaluation are studied. Thirdly, the characteristics of pharmaceutical industry are analyzed. Fourth, the performance evaluation index system of listed companies in pharmaceutical industry is constructed. The connotation of each index and the principles of standardized treatment of evaluation index and entropy weight method are expounded. Fifth, the performance evaluation method is studied, and the advantages of using catastrophe series method are analyzed. According to the data of 41 pharmaceutical industry listed companies controlled by state-owned assets in 2014, this paper makes a comprehensive analysis. Finally, this paper puts forward the relevant suggestions from the management level of listed companies. And how to improve the overall performance of the pharmaceutical industry put forward targeted recommendations.
【學位授予單位】：南京航空航天大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：F426.72

【參考文獻】

相關期刊論文 前10條

1 朱文濤;段利忠;石元元;張金鵬;喬延江;;基于《企業(yè)績效評價標準值》的醫(yī)藥全行業(yè)績效評價及預測[J];經濟與管理;2015年04期

2 曾錚;;中國醫(yī)藥產業(yè)發(fā)展概況及其趨勢研究[J];經濟研究參考;2014年32期

3 任珩;趙成章;安麗涓;;基于突變級數法的民勤綠洲水資源管理政策績效評價[J];資源科學;2014年05期

4 馮華;何佳莉;劉洋;;供應鏈物流能力績效評價體系的調研分析[J];中南財經政法大學學報;2014年01期

5 顧婧;田曉麗;;基于熵理論的高新技術企業(yè)投融資績效評價[J];統(tǒng)計與決策;2013年18期

6 黃祖慶;蔡文婷;張寶友;;利益相關者理論視角下物流服務供應鏈績效評價——以傳化物流為主導的物流服務供應鏈的實證[J];西安電子科技大學學報(社會科學版);2013年05期

7 李s，

本文編號：1861786